Literature DB >> 9495231

Prognosis of patients with ovarian cancer and borderline tumours diagnosed in Norway between 1954 and 1993.

T Bjørge1, A Engeland, S Hansen, C G Tropé.   

Abstract

The Scandinavian countries exhibit some of the highest incidence rates of ovarian cancer in the world. Prognosis is poor, and the crude 5-year relative survival was 36% in the Nordic countries in the 1980s. Histology-specific prognostic trends in 5-year relative survival of patients with ovarian cancer and borderline tumours were examined, based on data from the population-based Cancer Registry of Norway. Relative risks (RRs) of dying were derived from Cox regression models. Logistic regression analysis on the proportion of cases with a localised tumour was performed. The 5-year relative survival rate of patients with ovarian cancer increased steadily from 1954 to 1993, being most pronounced in women below the age of 65 at the time of diagnosis. No improvement was seen for women older than 75. For all patients with ovarian cancer, an RR of dying of 0.48 (95% CI = 0.44-0.53) was estimated in 1989-1993 compared with 1954-1958. For patients with epithelial cancer, an RR of 0.63 (95% CI = 0.57-0.69) was seen in 1989-1993 compared with 1970-1973. Patients with mucinous, endometrioid and clear cell tumours had the highest odds of having a localised tumour. The age-adjusted 5-year relative survival rate of patients with borderline tumours was almost constant between 1970 and 1993, at about 93%. The prognosis of patients with ovarian cancer in Norway has improved since the 1950s. The very favourable prognosis of patients with borderline tumours has remained unchanged since the 1970s.

Entities:  

Mesh:

Year:  1998        PMID: 9495231     DOI: 10.1002/(sici)1097-0215(19980302)75:5<663::aid-ijc1>3.0.co;2-x

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  11 in total

1.  Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas: A Population-based Clinicopathologic Study of 942 Cases.

Authors:  Russell Vang; Charlotte G Hannibal; Jette Junge; Kirsten Frederiksen; Susanne K Kjaer; Robert J Kurman
Journal:  Am J Surg Pathol       Date:  2017-06       Impact factor: 6.394

2.  A nationwide study of serous "borderline" ovarian tumors in Denmark 1978-2002: centralized pathology review and overall survival compared with the general population.

Authors:  Charlotte Gerd Hannibal; Russell Vang; Jette Junge; Kirsten Frederiksen; Anette Kjaerbye-Thygesen; Klaus Kaae Andersen; Ann Tabor; Robert J Kurman; Susanne K Kjaer
Journal:  Gynecol Oncol       Date:  2014-06-10       Impact factor: 5.482

3.  The chemokine, CXCL12, is an independent predictor of poor survival in ovarian cancer.

Authors:  A Popple; L G Durrant; I Spendlove; P Rolland; I V Scott; S Deen; J M Ramage
Journal:  Br J Cancer       Date:  2012-03-13       Impact factor: 7.640

4.  Evaluation of prevalent and incident ovarian cancer co-morbidity.

Authors:  K Stålberg; T Svensson; F Granath; H Kieler; B Tholander; S Lönn
Journal:  Br J Cancer       Date:  2012-05-01       Impact factor: 7.640

5.  TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival.

Authors:  Pedro Kringen; Yun Wang; Vanessa Dumeaux; Jahn M Nesland; Gunnar Kristensen; Anne-Lise Borresen-Dale; Anne Dorum
Journal:  BMC Cancer       Date:  2005-10-17       Impact factor: 4.430

6.  Ascitic complement system in ovarian cancer.

Authors:  L Bjørge; J Hakulinen; O K Vintermyr; H Jarva; T S Jensen; O E Iversen; S Meri
Journal:  Br J Cancer       Date:  2005-03-14       Impact factor: 7.640

7.  Secretion of soluble complement inhibitors factor H and factor H-like protein (FHL-1) by ovarian tumour cells.

Authors:  S Junnikkala; J Hakulinen; H Jarva; T Manuelian; L Bjørge; R Bützow; P F Zipfel; S Meri
Journal:  Br J Cancer       Date:  2002-11-04       Impact factor: 7.640

8.  Borderline ovarian tumours in Vaud, Switzerland: incidence, survival and second neoplasms.

Authors:  F Levi; C La Vecchia; L Randimbison; V C Te
Journal:  Br J Cancer       Date:  1999-01       Impact factor: 7.640

Review 9.  Ovarian tumors of low malignant potential.

Authors:  E L Trimble; C L Trimble
Journal:  Curr Treat Options Oncol       Date:  2001-04

10.  TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival.

Authors:  Y Wang; A Helland; R Holm; H Skomedal; V M Abeler; H E Danielsen; C G Tropé; A-L Børresen-Dale; G B Kristensen
Journal:  Br J Cancer       Date:  2004-02-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.